Factors associated with persistence of Golimumab treatment in the BIOBADASER registry, up to 7 years of follow-up
14/08/2023
M. Pombo1 , C. Sánchez-Piedra2 , L. Cea-Calvo3 , S. Manrique Arija4 , B. GarciaMagallon5 , C. Campos Fernández6 , I. Notario7 , F. Diaz-Gonzalez8 , J. J. GomezReino1
EULAR 2020
DOI: 10.1136/annrheumdis-2020-eular.3490
https://ard.bmj.com/content/79/Suppl_1/733.2